GAS5 and diffuse large B-cell lymphoma: Combination analysis of HOTAIR + GAS5 (Fig. 4F) revealed that a panel of baseline plasma HOTAIR plus GAS5 levels discriminated patients with different treatment outcome among DLBCL patients with AUC = 0.71 (95%CI = 0.574 to 0.824, P = 0.004), with optimal sensitivity and specificity of 72% and 61.02%, respectively.